Thrombocytopenias

Also known as: Thrombocytopenia / Thrombopenia / Thrombocytopaenia / Thrombocytopenia, unspecified / Thrombocytopenia NOS

DrugDrug NameDrug Description
DB11995AvatrombopagAvatrombopag (_Doptelet_), is an orally administered, small-molecule thrombopoietin receptor (c-Mpl) agonist which increases platelet number, but not platelet activation [A33097], [L2824]. This decreases the need for blood transfusions [L2824]. Patients with thrombocytopenia and chronic liver disease (leading to thrombocytopenia) often require platelet transfusions before surgical procedures to decrease the risk of bleeding [A33095]. Thrombocytopenia (or decreased numbers of platelets) is a common complication in patients suffering from chronic liver disease, either as an immediate result of liver disease or a consequence of interferon-based antiviral therapy [F95]. Avatrombopag was approved by the FDA on May 21, 2018 for thrombocytopenia (low platelets) in adults with chronic liver disease who are scheduled to undergo a procedure [L2931]. It is administered orally as _avatrombopag maleate_, its salt form [L2927]. _Doptelet_ (Avatrombopag) is the first orally administered treatment option for patients with chronic liver disease, allowing a large population of patients to avoid a platelet transfusion before a procedure by increasing platelet counts to the optimal level of greater or equal to 50,000 per microliter [L2932].
DB06210EltrombopagEltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy.
DB00038OprelvekinOprelvekin, the active ingredient in Neumega® is recombinant Interleukin eleven, which is produced in Escherichia coli (E. coli) by recombinant DNA technology. The protein has a molecular mass of approximately 19,000 daltons, and is non-glycosylated. The polypeptide is 177 amino acids in length (the natural IL-11 has 178). This alteration has not resulted in measurable differences in bioactivity either in vitro or in vivo. The primary hematopoietic activity of Neumega® is stimulation of megakaryocytopoiesis and thrombopoiesis. In mice and nonhuman primate studies Neumega® has shown potent thrombopoietic activity in compromised hematopoiesis, including moderately to severely myelosuppressed animals. In these studies, Neumega® improved platelet nadirs and accelerated platelet recoveries compared to controls. In animal studies Oprelvekin also has non-hematopoetic activities. This includes the regulation of intestinal epithelium growth (enhanced healing of gastrointestinal lesions), the inhibition of adipogenesis, the induction of acute phase protein synthesis (e.g., fibrinogen), and inhibition of macrophageal released pro-inflammatory cytokines.
DrugDrug NamePhaseStatusCount
DB09036Siltuximab0Withdrawn1
DB03496Alvocidib1Completed1
DB11995Avatrombopag1Completed1
DB08873Boceprevir1Completed1
DB11752Bryostatin 11Completed1
DB00091Ciclosporin1Completed1
DB06210Eltrombopag1Completed5
DB00480Lenalidomide1Completed1
DB01601Lopinavir1Completed1
DB12111MK-2121Completed1
DB00331Metformin1Active Not Recruiting1
DB00503Ritonavir1Active Not Recruiting1
DB00503Ritonavir1Completed1
DB00020Sargramostim1Completed1
DB05521Telaprevir1Completed1
DB01008Busulfan1 / 2Completed2
DB00987Cytarabine1 / 2Completed1
DB01262Decitabine1 / 2Completed1
DB06210Eltrombopag1 / 2Active Not Recruiting2
DB06210Eltrombopag1 / 2Terminated1
DB12121Entospletinib1 / 2Recruiting1
DB00773Etoposide1 / 2Completed1
DB00099Filgrastim1 / 2Completed1
DB01073Fludarabine1 / 2Completed2
DB00982Isotretinoin1 / 2Completed1
DB08935Obinutuzumab1 / 2Recruiting1
DB05332Romiplostim1 / 2Completed1
DB01030Topotecan1 / 2Completed1
DB00302Tranexamic acid1 / 2Not Yet Recruiting1
DB00316Acetaminophen2Active Not Recruiting1
DB00513Aminocaproic Acid2Recruiting1
DB11720Angiotensin 1-72Completed1
DB00098Antithymocyte immunoglobulin (rabbit)2Completed1
DB00023Asparaginase Escherichia coli2Completed1
DB11995Avatrombopag2Completed1
DB00928Azacitidine2Completed1
DB01008Busulfan2Recruiting1
DB00958Carboplatin2Completed1
DB00958Carboplatin2Terminated1
DB00493Cefotaxime2Recruiting1
DB00091Ciclosporin2Completed2
DB00515Cisplatin2Completed1
DB00531Cyclophosphamide2Completed1
DB00531Cyclophosphamide2Recruiting1
DB00531Cyclophosphamide2Terminated1
DB00987Cytarabine2Completed2
DB00987Cytarabine2Terminated1
DB00111Daclizumab2Completed1
DB00694Daunorubicin2Completed2
DB01262Decitabine2Completed1
DB01234Dexamethasone2Completed1
DB01234Dexamethasone2Recruiting1
DB11994Diacerein2Not Yet Recruiting1
DB00997Doxorubicin2Completed1
DB01257Eculizumab2Completed1
DB06210Eltrombopag2Active Not Recruiting3
DB06210Eltrombopag2Completed6
DB06210Eltrombopag2Not Yet Recruiting1
DB06210Eltrombopag2Recruiting3
DB06210Eltrombopag2Withdrawn1
DB00773Etoposide2Completed1
DB00773Etoposide2Terminated1
DB00099Filgrastim2Completed2
DB00099Filgrastim2Terminated1
DB01073Fludarabine2Recruiting1
DB00441Gemcitabine2Completed1
DB00762Irinotecan2Not Yet Recruiting1
DB00480Lenalidomide2Completed1
DB00650Leucovorin2Completed1
DB00825Levomenthol2Completed1
DB01033Mercaptopurine2Completed1
DB00563Methotrexate2Completed1
DB06650Ofatumumab2Completed1
DB00198Oseltamivir2Recruiting1
DB00019Pegfilgrastim2Terminated1
DB00008Peginterferon alfa-2a2Terminated1
DB00635Prednisone2Completed1
DB10415Rabbit2Completed1
DB00293Raltitrexed2Not Yet Recruiting1
DB00811Ribavirin2Completed1
DB00811Ribavirin2Terminated1
DB00073Rituximab2Terminated1
DB05332Romiplostim2Completed5
DB05332Romiplostim2Terminated3
DB00464Sodium Tetradecyl Sulfate2Terminated1
DB05521Telaprevir2Completed1
DB09499Thiosulfuric acid2Terminated1
DB00352Tioguanine2Completed1
DB00541Vincristine2Completed1
DB06151Acetylcysteine2 / 3Recruiting1
DB11121Chloroxylenol2 / 3Not Yet Recruiting1
DB11121Chloroxylenol2 / 3Unknown Status1
DB06210Eltrombopag2 / 3Recruiting1
DB06210Eltrombopag2 / 3Terminated1
DB06534Thrombopoietin2 / 3Unknown Status1
DB00945Acetylsalicylic acid3Terminated1
DB11995Avatrombopag3Terminated1
DB00928Azacitidine3Terminated1
DB00993Azathioprine3Recruiting1
DB00006Bivalirudin3Completed1
DB00493Cefotaxime3Active Not Recruiting1
DB00531Cyclophosphamide3Active Not Recruiting1
DB00531Cyclophosphamide3Recruiting1
DB01262Decitabine3Not Yet Recruiting1
DB06210Eltrombopag3Recruiting1
DB06210Eltrombopag3Terminated2
DB01073Fludarabine3Active Not Recruiting1
DB01611Hydroxychloroquine3Recruiting1
DB09053Ibrutinib3Active Not Recruiting1
DB13125Lusutrombopag3Completed1
DB00959Methylprednisolone3Recruiting1
DB00073Rituximab3Active Not Recruiting1
DB05332Romiplostim3Completed6
DB06534Thrombopoietin3Not Yet Recruiting1
DB00302Tranexamic acid3Recruiting1
DB00278Argatroban4Completed1
DB06210Eltrombopag4Withdrawn1
DB00569Fondaparinux4Active Not Recruiting1
DB11728Fondaparinux4Active Not Recruiting1
DB05332Romiplostim4Completed1
DB00877Sirolimus4Active Not Recruiting1
DB11995AvatrombopagNot AvailableTerminated1
DB12362Diaminopropanol tetraacetic acidNot AvailableNot Yet Recruiting1
DB12362Diaminopropanol tetraacetic acidNot AvailableRecruiting1
DB06210EltrombopagNot AvailableCompleted2
DB05332RomiplostimNot AvailableCompleted2
DB00853TemozolomideNot AvailableTerminated1